Skip to Main Content

Paper Details

In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts.
Pediatr Blood Cancer
0
2023
ALL, B-ALL, B-lineage, FLT3, FLT3 mRNA, Fms-related receptor tyrosine kinase 3, PDX, PDXs, SYK, SYK mRNA, Spleen tyrosine kinase, T-lineage, T-lineage PDXs, TAK-659, acute lymphoblastic leukemia, children, cytosolic nonreceptor tyrosine kinase, hematological malignancies, huCD45, human, human CD45, human CD45 cells, leukemia, mice, mivavotinib, patient, pediatric, pediatric ALL PDXs, pediatric ALL patient-derived xenografts, pediatric B-lineage ALL, pediatric acute lymphoblastic leukemia, tyrosine
Author NameAffiliation
Kathryn EvansChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Vivek M Philip
Steven B Neuhauser
Carol J Bult
Carol J Bult
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Richard B LockChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
  • 1 - 8

Datasets

Release 1.2